Based on the specific bioinformatics analyses on GDI2 based on The Cancer Genome Atlas (TCGA)-LIHC database, our results figured out that the GDI2 significantly over-expressed in tumor tissues of HCC patients compared with normal tissues (Figure 1), acting as a tumor booster in HCC progression. The gene discussed is GDI2; the disease is neoplasm.